Life sciences firm LabCorp has launched the new UltraQual Multiplex PCR Assay in the US for the detection of viruses in donated blood plasma, following the US Food and Drug Administration (FDA) approval.

Developed by the National Genetics Institute (NGI) laboratory, the test is designed to simultaneously identify hepatitis C virus (HCV), human immunodeficiency virus (HIV) 1 and 2, and hepatitis B virus (HBV) in a single sample.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“These plasma-derived therapies, known as biologics, replace missing or deficient proteins in a patient’s plasma to treat various well-defined medical conditions.”

When combined with NGI’s process to enhance testing throughput, UltraQual is said to offer improved turnaround time and value.

The assay is intended to aid biopharmaceutical companies that manufacture plasma-derived therapies in assessing the safety and availability of their medicines.

These plasma-derived therapies, known as biologics, replace missing or deficient proteins in a patient’s plasma to treat various well-defined medical conditions.

LabCorp Diagnostics chief scientific officer Marcia Eisenberg said: “This next-generation technology offers the international biopharmaceutical industry a differentiated solution to improve plasma donor collection programmes and the manufacturing of plasma protein therapies for a variety of life-threatening conditions including bleeding, immune, cardio/pulmonary and neurological disorders.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In March this year, LabCorp’s Covance Drug Development unit launched an immunology and immunotoxicology (I&I) unit focussed on catering to global biologic drug development needs.

The I&I unit, Covance’s expanded laboratory footprint, and LabCorp Diagnostics’ boost to its biologic therapeutic drug monitoring tests range are expected to support the company’s strategy to develop and commercialise new services for biologics market.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact